History of Corden Pharma Switzerland LLC

About Genzyme Pharmaceuticals

In 1982 Corden Pharma Switzerland LLC began as the acquisition of UK based Koch Light Laboratories by Genzyme Corporation to become Genzyme Fine Chemicals. Four years later when its focus shifted to pharmaceuticals, it was renamed Genzyme Pharmaceuticals.

In 1994 Genzyme Pharmaceuticals acquired Sygena AG, a Swiss facility focused on the production of high quality chemical intermediates and active pharmaceutical ingredients. The acquisition of the Sygena facility brought with it extensive peptide and amino acid derivative manufacturing capability while adding strength to an existing lipid development and manufacturing business.

The Swiss facility eventually became the cornerstone of production and R&D for the Pharmaceuticals Division of Genzyme. In 1999, to better reflect a unified vision and seamless working relationship between the Swiss operations and US Genzyme corporate offices in Cambridge, MA, Sygena officially changed its name to Genzyme Pharmaceuticals. Located in Liestal, near Basel, the facility holds a current GMP certificate and has been inspected by the Swiss Regulatory Agency, the US FDA, numerous customers and Genzyme Corporate Quality Compliance. To date these inspections have resulted in no reported critical observations.

On March 1, 2011 Genzyme Pharmaceuticals was purchased by International Chemical Investors Group (ICIG) to join their pharmaceutical affiliate Corden Pharma as Corden Pharma Switzerland LLC.

About International Chemical Investors Group and Corden Pharma

International Chemical Investors Group is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Since inception in 2004, ICIG has acquired 15 independently managed businesses, all of which have origins in major global chemical or pharmaceutical corporations. ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.

Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs and drug product formulations with more than 1,500 individuals supporting specialized technologies in all international markets.